arrow
D

Douglas A. Mata

foundation medicine
H指数:26
被引数:7,920

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phenotypic POLE variant classification identifies patients who may have favorable prognosis and benefit from immunotherapy

表型POLE变异分类识别可能具有良好预后并受益于免疫治疗的患者的群体

2026-01-020
PRE
Expanding the Clinicopathologic Spectrum of EWSR1::SSX-Rearranged Sarcomas: Series of 11 Cases Including Osteosarcomas and a Novel EWSR1::SSX4 Fusion

扩展EWSR1::SSX重排肉瘤的临床病理谱系:包含骨肉瘤和一种新型EWSR1::SSX4融合的11例病例系列研究

2025-10-240
PRE
High-Specificity Detection of Ultraviolet Mutational Signatures in Circulating Tumor DNA for Diagnostic Classification of Cutaneous and Unknown Primary Tumors using FoundationOne Liquid CDx

使用FoundationOne Liquid CDx对循环肿瘤DNA进行高特异性检测,以诊断分类皮肤癌和原发部位不明的肿瘤中的紫外线突变特征。

2025-08-200
OAAI
Technical Advance, FoundationOne CDx and FoundationOne Heme Detect Epstein-Barr Virus with High Sensitivity and Specificity

技术先进,FoundationOne CDx和FoundationOne Heme以高灵敏度和特异性检测EB病毒

2025-07-230
OAAI
Pan-tumor validation of a NGS fraction-based MSI analysis as a predictor of response to Pembrolizumab
2024-09-140
OAAI
Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results
2024-02-292
PRE
Novel SOX10 indel mutations drive schwannomas through impaired transactivation of myelination gene programs
2023-07-129
OAAI
POU2AF3-rearranged sarcomas: A novel tumor defined by fusions of EWSR1 or FUS to a gene formerly designated COLCA2
2023-03-319
PRE